SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: VVUS: VIVUS INC. (NASDAQ)

18 Jul 2002 09:15 PM
11 Jul 2002 09:28 PM
01 Jul 2002 05:32 PM
30 Jun 2002 07:16 AM
11 Jun 2002 08:30 PM
28 May 2002 09:16 PM
22 May 2002 06:58 AM
17 Apr 2002 08:31 PM
16 Apr 2002 10:38 PM
04 Apr 2002 09:28 PM
27 Mar 2002 08:43 PM
14 Mar 2002 09:02 PM
13 Mar 2002 08:58 PM
12 Mar 2002 09:55 PM
15 Feb 2002 08:44 AM
31 Jan 2002 09:47 PM
25 Jan 2002 02:03 PM
23 Jan 2002 10:11 PM
18 Jan 2002 08:30 PM
14 Jan 2002 06:49 AM
13 Jan 2002 08:25 AM
28 Dec 2001 08:17 PM
20 Dec 2001 10:41 PM <--
14 Dec 2001 04:51 PM
02 Dec 2001 12:35 AM
24 Jul 2001 09:57 AM
22 May 2001 07:54 AM
26 Jan 2001 09:40 PM
24 Jan 2001 10:14 PM
26 Dec 2000 04:24 PM
26 Oct 2000 08:09 PM
28 Sep 2000 07:52 PM
21 Jun 2000 04:45 PM
24 Sep 1997 10:59 PM

Return to VVUS: VIVUS INC. (NASDAQ)
 
Vivus (VVUS) C.E. Unterberg, Towbin raised its rating to "strong buy," pointing to important progress trials of the Vivus product Allista for the treatment of female sexual dysfunction.

GO to WWW.VIVUS.COM for complete product pipeline information.

CONTACT: VIVUS Inc.
Richard Walliser, 650/934-5200
ir@vivus.com
www.vivus.com
or
Lippert/Heilshorn & Associates Inc.
Bruce Voss, 310/691-7100 (Investor Contacts)
bvoss@lhai.com
Jody Cain, 310/691-7100 (Investor Contacts)
jcain@lhai.com
Elissa Grabowski, 212/838-3777 (Media Contact)
egrabowski@lhai.com
www.lhai.com

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News